Tardive Dyskinesia and Problems of Assessment

  • Thomas Barnes
  • Tim Kidger

Abstract

Tardive dyskinesia (TD) is a movement disorder first described by Schonecker in 1957. Although spontaneous cases do occur it is most frequently a drug-induced phenomenon. The syndrome was slow to be recognised, partly perhaps because of the natural resistance of clinicians to accept any iatrogenic condition (Crane, 1973a). In addition TD was largely confined to psychotic patients in long-stay wards, probably the population attracting the least intensive medical involvement. Superficially the abnormal movements may resemble schizophrenic stereotypies and clinically the condition is easily overlooked especially as patients rarely complain spontaneously (Paulson, 1975).

Keywords

Dopamine Neurol Choline Lecithin Dystonia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alien, R. E. and Stimmel, G. L. (1977). Neuroleptic dosage, duration and T.D. Dis. Nerv. Syst., 38, 385–387Google Scholar
  2. American College of Neuropsychopharmacology — Food and Drug Administration Task Force (1973). Neurologic syndromes associated with anti-psychotic drug use. New Engl. J. Med., 289, 20–23CrossRefGoogle Scholar
  3. Ayd, F. J., Jr. (1970). Prevention of recurrence (maintenance therapy). Clinical Handbook of Psychopharmacology (Ed. A. DiMascio and R. I. Schader), Science House, New York, pp. 297–310Google Scholar
  4. Birket-Smith, E. (1974). Abnormal involuntary movements induced by anticholinergic therapy. Acta neurol. scand., 50, 801–811PubMedCrossRefGoogle Scholar
  5. Bockenheimer, S. and Lucius, G. (1976). Zer Therapie mit Dimethyl Aminoethanol (Deanol) bei Neuroleptikain Duzierten Extrapyramidalen Hyperkinesen. Arch. Psychiat., 222, 69–75CrossRefGoogle Scholar
  6. Bourgeois, M. and Herbert, A. (1970). Les Dyskinesies Tardives des Neuroleptiques. Bord. Med., 3, 345–352PubMedGoogle Scholar
  7. Brandon, S., McClelland, H. A. and Protheroe, C. (1971). A study of facial dyskinesia in a mental hospital population. Br. J. Psychiat., 118, 171–184CrossRefGoogle Scholar
  8. Brandrup, E. (1961). Tetrabenazine treatment in persisting dyskinesia caused by psychopharmaca. Am. J. Psychiat., 118, 551–552PubMedCrossRefGoogle Scholar
  9. Bucci, L. (1971). The dyskinesias: a new therapeutic approach. Dis. Nerv. Syst., 32, 324–327PubMedGoogle Scholar
  10. Carroll, B. J., Curtis, G. C. and Kokmen, E. (1977). Paradoxical response to dopamine agonists in tardive dyskinesia. Am. J. Psychiat., 134 (7), 785–789PubMedCrossRefGoogle Scholar
  11. Carruthers, S. G. (1971). Persistent tardive dyskinesia. Br. Med. J., 3, 572PubMedCentralPubMedCrossRefGoogle Scholar
  12. Casey, D. E. (1977). Deanol: a survey of opinions by experts. Convulsive Ther. Bull., 2 (3), 50–51Google Scholar
  13. Casey, D. E. and Denney, D. (1975). Deanol in the treatment of T.D. Am. J. Psychiat., 132, 8Google Scholar
  14. Chadwick, D., Reynolds, E. H. and Marsden, C. D. (1976). Anticonvulsant induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J. Neurol. Neurosurg. Psychiat., 39, 1210–1218PubMedCentralPubMedCrossRefGoogle Scholar
  15. Claveria, L. E., Teychenne, P. F., Caine, D. B. et al. (1975). Tardive dyskinesia treated with pimozide J. nurol. Sci., 24, 393–401CrossRefGoogle Scholar
  16. Crane, G. E. (1968). T.D. in patients treated with major neuroleptics. Am. J. Psych., 124 (Suppl.), 40–48CrossRefGoogle Scholar
  17. Crane, G. E. (1971a). More on amantidine in tardive dyskinesia. New Engl. J. Med., 285, 1150–1151PubMedGoogle Scholar
  18. Crane, G. E. (1971b). Persistence of neurological symptoms due to neuroleptic drugs. Am. J. Psychiat., 127, 1407–1410PubMedCrossRefGoogle Scholar
  19. Crane, G. E. (1973a). Persistent dyskinesia. Br. J. Psychiat., 122, 395–405CrossRefGoogle Scholar
  20. Crane, G. E. (1973b). Rapid reversal of tardive dyskinesia. Am. J. Psychiat., 130, 11–59CrossRefGoogle Scholar
  21. Crane, G. E. (1975). Deanol for tardive dyskinesia. New Engl. J. Med., 292, 926–928CrossRefGoogle Scholar
  22. Crane, G. E., Ruiz, P., Kernohan, W. J., et al. (1969). Effects of drug withdrawal in tardive dyskinesia. Activitas nerv. sup., 11, 30–35Google Scholar
  23. Crane, G. E., Turek, I. S. and Kurland, A. A. (1970). Failure of pyridoxine to reduce drug-induced dyskinesias. J. Neurol. Neurosurg. Psychiat., 33, 511–512PubMedCentralPubMedCrossRefGoogle Scholar
  24. Dalen, P. (1973). Lithium therapy in Huntington’s chorea and tardive dyskinesia. Lancet i 107–108CrossRefGoogle Scholar
  25. Davis, K. L., Berger, P. A. and Hollister, L. E. (1975). Choline for tardive dyskinesia. New Engl. J. Med., 293, 152PubMedGoogle Scholar
  26. Davis, K. L., Berger, P. A. and Hollister, L. E. (1977). Deanol in tardive dyskinesia. Am. J. Psychiat., 134, 807PubMedCrossRefGoogle Scholar
  27. Davis, K. L., Hollister, L. E., Barchas, J. D., et al. (1976). Choline in T.D. and Huntington’s disease. Life Sci., 19, 1507–1516PubMedCrossRefGoogle Scholar
  28. Decker, B.L., Davis, J.M., Janowsky, D. S.,et al. (1971). Amantidine hydrochloride treatment of tardive dyskinesia. New Engl. J. Med., 285, 860PubMedGoogle Scholar
  29. Degkwitz, R. and Wenzel, W. (1976). Persistent extrapyramidal side effects after long term application of neuroleptics. Neuropsychopharmacology (International Congress series 129)Google Scholar
  30. Degkwitz, R., Wenzel, W., Binsack, K. F., Herkert, H. and Luxenburger,O. (1966). Zum Probleme Der Terminalen Extrapyramidalen Hyperkinesen an Hand von 1600 Langfristig mit Neuroleptica Behandelten. Artzneimittel Forschung 16 276–278Google Scholar
  31. DeSilva, L. and Huang, C. Y. (1975). Deanol in tardive dyskinesia. Br. med. J., 3, 466CrossRefGoogle Scholar
  32. Dynes, J. B. (1970). Oral dyskinesias, occurrence and treatment. Dis. Nerv. Syst. 31 854–859PubMedGoogle Scholar
  33. Eckmann, F. (1968). Zur Problematik von Dauerschaden nach neuroleptischer langzeit Behandelung. Ther. Ggw., 107, 316–323PubMedGoogle Scholar
  34. Ehrensing, R. H., Kastin, A. H., Larsons, P. F. and Bishop, G. A. (1977). Melanocytestimulating-hormone-release-inhibiting-factor I and tardive dyskinesia. Dis. Nerv. Syst., 38 (4), 303–307PubMedGoogle Scholar
  35. Escobar, J. I. and Kemp, K. F. (1975). Dimethylaminoethanol for tardive dyskinesia. New Engl. J. Med., 292, 317–318PubMedCrossRefGoogle Scholar
  36. Fann, W. and Lake, C. R. (1974). On the coexistence of parkinsonism and tardive dyskinesia. Dis. Nerv. Syst., 35, 324–326PubMedGoogle Scholar
  37. Fann, W., Lake, C. R., Gerber, C. J. et al. (1974). Cholinergic suppression of tardive dyskinesia. Psychopharmacologia, 37, 101–107PubMedCrossRefGoogle Scholar
  38. Fann, W., Lake, C. R. and McKenzie, G. M. (1974). Proceedings: adrenergic and cholinergic factors in extrapyramidal disorders. Psychopharmac. Bull., 10 (3), 52–53Google Scholar
  39. Fann, W., Stafford, J. R., Malone, R. L., Frost, J. D. and Richman, B. W. (1977). Clinical research techniques in tardive dyskinesia. Am. J. Psychiat., 134 (7), 759–762PubMedCrossRefGoogle Scholar
  40. Fann, W. E., Sullivan, J. L. and Richman, B. W. (1976). Dyskinesias associated with tricyclic antidepressants. Br. J. Psychiat., 128, 490–493CrossRefGoogle Scholar
  41. Farrar, W. B. (1976). Using electromyographic biofeedback in treating orofacial dyskinesia. J. Prosthet. Dent., 35, 384–387PubMedCrossRefGoogle Scholar
  42. Faurbye, A., Rasch, P. J., Peterson, P. B., Brandborg, G. and Pakkenberg, H. (1964). Neurological symptoms in pharmacotherapy of psychoses. Acta psychiat. stand., 40, 10–27CrossRefGoogle Scholar
  43. Gardos, G., Cove, J. O. and Sniffen, C. (1976). An evaluation of papaverine in tardive dyskinesia. J. clin. Pharmac., 16, 304–310CrossRefGoogle Scholar
  44. Gerlach, J., Reisby, N. and Randup, A. (1974). Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia (Berl.), 34, 21–35CrossRefGoogle Scholar
  45. Gilbert, M. M. (1969). Haloperidol in severe facial dyskinesia. Dis. Nerv. Syst., 30, 481–482PubMedGoogle Scholar
  46. Godwin-Austin, R. B. and Clark, T. (1971). Persistent phenothiazine dyskinesia treated with tetrabenazine. Br. med. J., 4, 25–26CrossRefGoogle Scholar
  47. Goldman, D. (1976). Treatment of phenothiazine-induced dyskinesia. Psychopharmacology, 47, 271–272PubMedCrossRefGoogle Scholar
  48. Greenblatt, D. L., Shader, R. I. and DiMascio, A. (1970). Extra-pyramidal effects. In Psychotropic Drug Side Effects (Ed. R. I. Shader and A. DiMascio) Williams and Wilkins Co., Baltimore, pp. 92–106Google Scholar
  49. Growden, J. H., Hirsch, M. J., Wurtman, R. J. and Wiener, W. (1977). Oral choline administration to patients with tardive dyskinesia. New Engl. J. Med., 297, 524–5277CrossRefGoogle Scholar
  50. Guilleminault, C., Tharp, B. R. and Cousin, D. (1973). HVA+5HIAA CSF measurements and 5HTP trials in some patients with involuntary movements. J. neurol. Sei., 18, 435–441CrossRefGoogle Scholar
  51. Haddenbrock, S. (1964). Hyperkinetische Dauersyndrome nach hochdosierter und lang Streckerbehandlung mit Neuroleptika. In Begreiterscheinungen und Misserfolge der Psychiatrischen Pharmakotherapie (Ed. H. Kranz and K. Heinrich ), Georg Thieme, Stuttgart, pp. 54–63Google Scholar
  52. Hirsch, M. J., Growdon, J. H. and Wurtman, R. J. (1977). Oral choline administration to patients with tardive dyskinesia. Meeting of American Academy of NeurologyGoogle Scholar
  53. Hunter, R., Earl, C. J. and Thornicroft, S. (1964). An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proc. R. Soc. Med., 57, 758–762PubMedCentralPubMedGoogle Scholar
  54. Joyston-Bechal, M. P. (1965). Persistent oral dyskinesia in treatment with phenothiazine derivatives. Lancet, i, 600–601CrossRefGoogle Scholar
  55. Jus, A., Pineau, R., Lachance, R., Pelchat, G., Jus, K., Pires, P. and Villeneuve, R. (1976a). Epidemiology of tardive dyskinesia, Part I. Dis. Nerv. Syst., May, 210–214Google Scholar
  56. Jus, A., Pineau, R., Lachance, R., Pelchat, G., Jus, K., Pires, P. and Villeneuve, R. (1976b). Epidemiology of tardive dyskinesia, Part II. Dis. Nerv. Syst., May, 257–261Google Scholar
  57. Jus, A., Gautier, J., Villeneuve, A., Jus, K., Pires, P. and Gagnon-Binette, M. (1977). Chronology of combined neuroleptic and antiparkinsonian administration. Am. J. Psychiat., 134, 11–57CrossRefGoogle Scholar
  58. Jus, K., Jus, A. and Villeneuve, A. (1973). Polygraphic profile of oral tardive dyskinesia and of rabbit syndrome for quantitative and qualitative evaluation. Dis. Nerv. Syst., 34, 27–32PubMedGoogle Scholar
  59. Kazamatsuri, H., Chien, C. and Cole, J. O. (1972a). Treatment of tardive dyskinesia I. Clinical efficacy of a dopamine depleting agent tetrabenazine. Archs gen. Psychiat., 27, 95–99CrossRefGoogle Scholar
  60. Kazamatsuri, H., Chien, C. and Cole, J. O. (1972b). Treatment of tardive dyskinesia II. Short term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Archs gen. Psychiat., 27, 100–103CrossRefGoogle Scholar
  61. Kazamatsuri, H., Chien, C. and Cole, J. O. (1972c). Treatment of tardive dyskinesia III. Clinical efficacy of a dopamine competing agent, methyl dopa. Archs gen. Psychiat., 27, 824–827CrossRefGoogle Scholar
  62. Kazamatsuri, H., Chien, C. and Cole, J.O. (1973). Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am. J. Psychiat., 130, 479–483PubMedGoogle Scholar
  63. Kennedy, P. F. (1969). Chorea and phenothiazines. Br. J. Psychiat., 115, 103–104CrossRefGoogle Scholar
  64. Klawans, H. L. Jr. (1973a). The pharmacology of tardive dyskinesias. Am. J. Psychiat., 130, 82–86PubMedCrossRefGoogle Scholar
  65. Klawans, H. L. Jr. (1973b). The pharmacology of extrapyramidal movement disorders. Monogr. nurol. Sci., 2, 1–136Google Scholar
  66. Klawans, H. L. and Rubovits, R. (1974). Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J. Neurol. Neurosurg. Psychiat., 37, 941–947PubMedCentralPubMedCrossRefGoogle Scholar
  67. Klett, C.J., Point, P. and Caffrey, E. (1972). Evaluating the long term need for antiparkinson drugs by chronic schizophrenics. Archs gen. Psychiat., 26, 374–379CrossRefGoogle Scholar
  68. Kobayashi, R. M. (1976). Orofacial dyskinesia—clinical features, mechanisms and drug therapy. West J. Med., 125, 277–288PubMedCentralPubMedGoogle Scholar
  69. Korsgaard, S. (1976). Baclofen (Lioresal) in the treatment of neuroleptic induced tardive dyskinesia. Acta psychiat. scand., 54, 17–24PubMedCrossRefGoogle Scholar
  70. Kumar, B. B. (1976). Treatment of tardive dyskinesia with deanol. Am. J. Psychiat., 133, 978CrossRefGoogle Scholar
  71. Kunin, R. A. (1976). Manganese and niacin in the treatment of drug-induced dyskinesias. J. Orthnomoleculat. Psychiat., 5, 4–27Google Scholar
  72. Linden,D. (1977). Treatment of dyskinesia. New Engl. J. Med., 296(17), 1004–1005Google Scholar
  73. Linnoila, M., Viukari, M. and Hietala, O. (1976). Effect of sodium valproate on TD. Br. J. Psychiat., 129, 114–119CrossRefGoogle Scholar
  74. McCallum, W. A. G. (1970). Tetrabenazine for extra-pyramidal movement disorders. Br. J. Med., 1, 760CrossRefGoogle Scholar
  75. Mehta, D., Mehta, S. and Mathew, P. (1976). Failure of deanol in treating tardive dyskinesia. Am. J. Psychiat., 133, 1467PubMedCrossRefGoogle Scholar
  76. Merren, M. D. (1972). Amantidine tri tardive dyskinesia. New Engl. J. Med., 286, 268PubMedGoogle Scholar
  77. Miller, E. M. (1974). Deanol: a solution for tardive dyskinesia. New Engl. J. Med., 291, 796–797PubMedGoogle Scholar
  78. Nashold, B. S. (1969). The effects of central tegmental lesions on tardive dyskinesia. In Psychotropic Drugs and Dysfunctions of the Basal Ganglia (Ed. Crane and Gardner Jr.), Public Health Service Publication, Washington D.C., pp. 111–113Google Scholar
  79. O’Flanagan, P. M. (1975). Clonazepam in the treatment of drug induced dyskinesia. Br. Med. J., 1, 269–270PubMedCentralPubMedCrossRefGoogle Scholar
  80. Pakkenberg, H. and Fog, R. (1974). Spontaneous oral dyskinesia: results of treatment with tetrabenazine, pimozide, or both. Archs Neurol., 31, 352–353CrossRefGoogle Scholar
  81. Paulson, G. W. (1971). Use of pyridoxine in chorea. Am. J. Psychiat., 127, 1091PubMedCrossRefGoogle Scholar
  82. Paulson, G. W. (1975). Tardive dyskinesia. A. Rev. Med., 26, 75–81CrossRefGoogle Scholar
  83. Pearce, J. (1971). Mechanism of action of amantidine. Br. med. J., 3, 529PubMedCentralPubMedCrossRefGoogle Scholar
  84. Prange, A. J., Wilson,I. C., Morris, C. E. (1973). Preliminary experience with tryptophan and lithium in the treatment of tardive dyskinesia. Psychopharmac. Bull., 9, 36–37Google Scholar
  85. Pryce, I. J. and Edwards, H. (1966). Persistent oral dyskinesia in female mental hospital patients. Br. J. Psychiat. 112 983–987CrossRefGoogle Scholar
  86. Quitkin, F., Rifkin, A., Gochfeld, L. and Klein, D. F. (1977). Tardive dyskinesia: are the first signs reversible? Am. J. Psychiat., 134 (1), 84–87PubMedCrossRefGoogle Scholar
  87. Reda, F. A., Scanlan, J.M., Kemp, K. and Escobar,J. I. (1974). Treatment of tardive dyskinesia with lithium carbonate. New Engl. J. Med., 291, 850PubMedGoogle Scholar
  88. Rosin, A. J. and Exton-Smith, A. M. (1965). Persistent oral dyskinesia in treatment with phenothiazine derivatives. Lancet, i, 651Google Scholar
  89. Roxburgh, P. A. (1970). Treatment of persistent phenothiazine induced oral dyskinesia. Br. J. Psychiat., 116, 277–280CrossRefGoogle Scholar
  90. Sato, S., Daly, R. and Peters, H. (1971). Reserpine therapy of phenothiazine induced dyskinesia. Dis. Nerv. Syst., 32, 680–685PubMedGoogle Scholar
  91. Schmidt, W. R. and Jarcho, L. W. (1966). Persistent dyskinesia following phenothiazine therapy. Archs Neurol., 14, 369–377CrossRefGoogle Scholar
  92. Schonecker, M. (1957). Ein eigentumliches Syndrom in ovalen Bereich bei Megaphen Applikation. Nervenarzt, 28, 35–42Google Scholar
  93. Sedman, G. (1976). Clonazepam in treatment of tardive oral dyskinesia. Br. med. J., 2, 583PubMedCentralPubMedCrossRefGoogle Scholar
  94. Simpson, G. M., Branchey, M. H., Lee, J. H. et al. (1976). Lithium in tardive dyskinesia. Pharmakopsychologis, 9, 76–80CrossRefGoogle Scholar
  95. Simpson, G. M. and Varga, E. (1974). Clozapine— a new antipsychotic agent. Curr. ther. Res., 16, 679–686PubMedGoogle Scholar
  96. Singer, R. and Cheng, M. N. (1971). Thiopropazate hydrochloride in persistent dyskinesia. Br. med. J., 4, 22–25PubMedCentralPubMedCrossRefGoogle Scholar
  97. Singh, M. M. (1976). Diazepam in the treatment of tardive dyskinesia. Int. Pharmaco Psychiat., 11, 232–234Google Scholar
  98. Sutcher, H. D., Underwood, R. B., Beatty, R. A. et al, (1971). Orofacial dyskinesia, a dental dimension. J. Am. med. Ass., 216, 1459–1463CrossRefGoogle Scholar
  99. Tamminga, C. A., Smith,R.C., Ericksen, S. E., Chang, S., Davis, J. M. (1977). Cholinergic influences in tardive dyskinesia. Am. J. Psychiat. 134(7) 769–774PubMedCrossRefGoogle Scholar
  100. Tarsy, D., Leopold, N. and Sax, D. S. (1974). Physostigmine in choreiform movement disorders. Neurology, 24, 28–33PubMedCrossRefGoogle Scholar
  101. Uhrbrand, L. and Faurbye, A. (1960). Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and ECT. Psychopharmacologia, 1, 408–418CrossRefGoogle Scholar
  102. Vale, S. and Espejel, M. A. (1971). Amantidine for dyskinesia tarda. New Engl. J. Med., 284, 673PubMedGoogle Scholar
  103. Villeneuve, A. and Böszörmenyi, Z. (1970a). Treatment of drug induced dyskinesias. Lancet, i, 353–354CrossRefGoogle Scholar
  104. Villeneuve, A., Böszörmenyi, Z., Dechambault, M., et al. (1970b). Tentative de traitment de dyskinesia post-neuroleptique de type permanent. Laval Med., 41, 923–933PubMedGoogle Scholar
  105. Vinkari, M. and Linnoila, M. (1975). Effect of methyl dopa on tardive dyskinesia in psychogeriatric patients. Curr. ther. Res., 18 (3), 417–424Google Scholar
  106. Wertheimer, J. (1965). Syndromes extra-pyramidaux permanents consecutifs a l’administration prolongée de neuroleptiques. Schweiz. Arch. Neurol. Neurochir. Psychiat., 95, 120–173Google Scholar
  107. Widroe, H. J. and Heisler, S. (1976). Treatment of tardive dyskinesia. Dis. Nerv. Syst., March, 162–164Google Scholar
  108. Wurtman, R. J., Hirsch, M. J. and Growdon, J. H. (1977). Lecithin consumption raises serum free choline levels. Lancet, ii, 68–69CrossRefGoogle Scholar

Copyright information

© Raghu N. Gaind and Barbara L. Hudson 1979

Authors and Affiliations

  • Thomas Barnes
  • Tim Kidger

There are no affiliations available

Personalised recommendations